Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease
- Conditions
- Non-erosive Gastroesphageal Reflux Disease
- Interventions
- Registration Number
- NCT04325620
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Brief Summary
The purpose of this study is to investigate the safety and clinical efficacy of HIP1601 in patients with Non-erosive gastroesphageal reflux disease.
- Detailed Description
A Multicenter, Randomized, Parallel, Double-Blinded, Placebo-controlled Phase Ⅲ Study to Compare Efficacy and Safety of HIP1601 in Patients with Non-Erosive Gastroesophageal Reflux Disease(NERD)
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 208
- 19≤ age ≤ 75
- Patients who were not observed mucosal break('not present') according to the LA classification(LA grade) on the EGDEsophago-Gastro-Duodenoscopy
- Patients who had experienced major symptom within 3 months Patients experienced heartburn or acid regurgitation within 7 days of screening day
- Patients who had experienced major symptom within 7 days before randomization. Entry into study also required that patients had experienced at least mild symptoms on at least 2 days/week or at least moderate symptoms on at least 1 day/week based on RDQ
- Patients understood the consents and purpose of this trial and signed consent form
- Patients who have erosive GERD, Barrett's esophagus(other significant dysplasia of esophagus), gastroesophageal varicose veins, active peptic ulcer, gastrointestinal bleeding or malignant GI tumor confirmed by endoscopy
- Patients who have a history of gastric or gastroesophageal surgery
- Patients who have Zollinger-Ellison syndrome, eosinophilic esophagitis, primary esophageal motility disorder, acute upper gastrointestinal bleeding, Functional dyspepsia, IBS, IBD within 3 months before Visit 1
- Patients with clinically significant liver, kidney, nervous system, respiratory, endocrine, hematologic, cardiovascular, urinary system disease.
- Patients Has a severe liver disorder(AST or ALT level exceeds 3 times more than normal upper range at Visit 1)
- Has a clinically significant renal failure(MDRD eGFR ≤ 59 mL/min/1.73m2 or Serum creatinine >2.0mg/dL at Visit 1)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description HGP1805 HGP1805 The participants will receive tretment of HGP1805(Placebo of HIP1601), orally, once daily for 4weeks. HIP1601 Amg HIP1601 The participants will receive tretment of HIP1601 Amg, orally, once daily for 4weeks.
- Primary Outcome Measures
Name Time Method Percentage of patients with complete resolution of major symptoms at 4-week 4 week Complete resolution is defined as no episodes of symptom during the last 7 days of treatment.
- Secondary Outcome Measures
Name Time Method Major symptoms-Free days 1, 4 week Major symptoms-Free days mean rate of days that symtom's severity score is '0' using subject's diary
Frequency and Severity of Reflux disease symptom assessment using Reflux Disease Questionnaire(RDQ) 2, 4 week RDQ frequncy and severity score is 0 to 5 point scale, high score mean a worse outcome.
Percentage of patients with complete resolution of major symptoms at 2-week 2 week Complete resolution is defined as no episodes of symptom during the last 7 days of treatment
Time to complete resolution of major symptoms 4 week defined as time to the first day of complete resolution
Quality of Life assessment using Patient Assessment of upper Gastrointestinal disorders-Quality of Life(PAGI-QoL) 4 week PAGI-QoL total score is 0 to 30 point scale, high score mean a better outcome.
Resolution rate of major symptoms of first 7 days 1 week defined as first of 7 days with no episodes of symptom using subject's diary
Proportion of rescue medication amounts 4 week Use of rescue medication
Trial Locations
- Locations (1)
Seoul National University Bundang Hospital
🇰🇷Seongnam, Gyeonggi-do, Korea, Republic of